PPLPHARMAPharmaceuticals
Piramal Pharma Ltd — PE Ratio & Valuation Analysis
₹136.54
+1.77%
Current P/EN/AxPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E730.4x100.0% below avg
✅
100.0% Discount to Industry
PPLPHARMA P/E N/Ax vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹0.68 | ₹172 | 253.3x |
| 2024 | ₹0.14 | ₹266 | 1901.8x |
| 2022 | ₹3.09 | ₹112 | 36.2x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Piramal Pharma Ltd Valuation
Piramal Pharma Ltd (PPLPHARMA) currently trades at N/Ax earnings. The Pharmaceuticals sector average PE is 31.77x. Historically, PPLPHARMA has traded at an average PE of 730.4x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
1.11%
Dividend Yield
0.08%
More on Piramal Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.